MDGL · Madrigal Pharmaceuticals, Inc.
$546.79
+11.10 (+2.07%)
At close · Jul 21
Market Cap
$12.61B
Shares
23.06M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$958.4M
+432.1%
FY2025
Net Income
-$288.28M
+38.1%
FY2025
Gross Margin
96.54%
FY2024
Operating Margin
-31.31%
+245.1pp
FY2025
Diluted EPS
-$12.85
+41.3%
FY2025
Operating Cash Flow
-$189.55M
+58.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.13B | $958.4M | $180.13M | $0 | $0 | $0 | $0 | $0 | — | — | — | — | $147K | — | — | — | |
| — | — | $6.23M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $173.9M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | 96.54% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $453.05M | $388.53M | $236.72M | $272.35M | $245.44M | $205.16M | $184.81M | $72.32M | $25.39M | $24.39M | $15.93M | $54.22M | $68.21M | $71.86M | $49.41M | $41.46M | |
| — | — | — | $108.15M | $48.13M | $37.32M | $21.86M | $22.65M | $15.29M | $7.67M | $9.29M | $13.39M | $15.75M | $15.7M | $11.68M | $11.55M | |
| $914.47M | $813.83M | $435.06M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $1.51M | $1.1M | $527K | $467K | $405K | $471K | $112K | $96K | $77K | $156 | $662K | $673K | $516K | $738K | $1.46M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $1.24M | |
| $1.45B | $1.26B | — | $380.5M | $293.57M | $242.48M | $206.67M | $94.97M | $40.68M | $32.06M | $25.22M | $67.61M | $83.95M | $87.56M | $61.09M | $53.02M | |
| — | — | $678.01M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$313.51M | -$300.1M | -$497.88M | -$380.5M | -$293.57M | -$242.48M | -$206.67M | -$94.97M | -$40.68M | -$32.06M | -$25.22M | -$67.61M | -$83.95M | -$87.56M | -$60.94M | -$45.43M | |
| — | -31.31% | -276.39% | — | — | — | — | — | — | — | — | — | -57109.52% | — | — | — | |
| — | -$298.59M | -$496.78M | -$379.97M | -$293.1M | -$242.08M | -$206.2M | -$94.86M | -$40.59M | -$31.99M | -$25.22M | -$66.95M | -$83.28M | -$87.04M | -$60.2M | -$43.97M | |
| $26.83M | $22.31M | $14.67M | $12.71M | $3.96M | — | — | — | $1.21M | $1.21M | $1.21M | — | — | — | — | — | |
| $36.24M | $37.36M | $46.65M | $19.58M | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$2.56M | -$463K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| -$309.44M | -$288.28M | -$465.89M | -$373.63M | -$295.35M | -$241.85M | -$202.24M | -$83.95M | -$32.81M | -$31.15M | — | — | — | — | — | — | |
| — | -30.08% | -258.64% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$31.52M | — | — | — | — | — | — | — | — | -$31.15M | -$26.39M | -$68.67M | -$86.16M | -$90.19M | -$62.79M | -$47.38M | |
| -$308.74M | -$287.88M | -$465.89M | -$373.13M | -$295.3M | -$241.97M | -$202.41M | -$83.41M | -$33.1M | -$31.21M | -$26.36M | -$68.67M | -$86.17M | -$90.18M | -$62.79M | — | |
| USD/shares | — | -$12.85 | -$21.90 | -$19.99 | -$17.23 | — | — | — | — | — | — | — | — | — | — | -$1.00 |
| USD/shares | — | -$12.85 | -$21.90 | -$19.99 | -$17.23 | — | — | — | — | — | — | — | — | — | — | -$1.00 |
| shares | — | 22.43M | 21.27M | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.8M | 12.24M | 5.2M | 128.59M | 98.49M | 70.98M | 59.41M | 47.2M |
| shares | — | 22.43M | 21.27M | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.8M | 12.24M | 5.2M | 128.59M | 98.49M | 70.98M | 59.41M | 47.2M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2014: $96K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.03×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $958,403,000 | $180,133,000 | $0 |
Key facts
CIK
1157601
CUSIP
558868105
13F (30d)
41 filings
40 filers
Visit website
Investor relations